Please assess the completion status of the following clinical trial:

Trial Title: RAL-eve Study: Raltegravir Substitution Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.~2. ART for at least 6 months prior to study entry with a regimen that includes enfuvirtide.~3. Self-defined infusion site reaction to enfuvirtide (usually will be painful inflammatory nodules)~4. No change in ART regimen for at least 3 months prior to study entry.~5. CD4+ cell count \>50/mm3 at screening (obtained within 60 days prior to study entry).~6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive assay~7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the limits of quantification on all tests, except as explained above in section 4.1.6 for a single detectable viral load of \<50 copies but \<200 copies in last 6 months.~8. Laboratory values obtained within 60 days prior to entry:~   * Absolute neutrophil count (ANC) \>750/mm3~  * Hemoglobin \>9.0 g/dL for female subjects and\>10.0 g/dL for male subjects~  * Platelet count \>50,000/mm3~  * Calculated creatinine clearance (CrCl) \>30 mL/min, as estimated by the Cockcroft-Gault equation\*~  * AST (SGOT), ALT (SGPT), and alkaline phosphatase \<5 x ULN~  * Total bilirubin \<2.5 x ULN. If the subject is taking an indinavir- or atazanavir-containing regimen at the time of screening, total bilirubin \<5 x ULN is acceptable.~9. For females of reproductive potential will need a negative serum or urine pregnancy test within 48 hours prior to entry.~10. Men and women age \>18 years.~11. Ability and willingness of subject to provide informed consent.~Exclusion Criteria:~1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.~2. Breast-feeding or pregnancy.~3. An opportunistic infection within 60 days prior to entry.~4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.~5. Active drug or alcohol use or dependence that, in the opinion of the Protocol Director, would interfere with adherence to study requirements.~6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for receipt of vaccination during the study.~7. Plan to change the background ART within 24 weeks after study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).